Ionis Pharmaceuticals Inc (NASDAQ:IONS) – Svb Leerink raised their FY2019 earnings per share estimates for Ionis Pharmaceuticals in a research note issued on Thursday, December 5th. Svb Leerink analyst M. Foroohar now expects that the company will post earnings per share of $1.64 for the year, up from their prior estimate of $1.60. Svb Leerink also issued estimates for Ionis Pharmaceuticals’ Q3 2020 earnings at $0.16 EPS, Q4 2020 earnings at $0.29 EPS and FY2020 earnings at $0.44 EPS.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.18 EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.49. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The firm had revenue of $168.00 million during the quarter, compared to analysts’ expectations of $152.47 million. During the same period in the previous year, the company earned ($0.03) EPS. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year.
Shares of IONS opened at $62.91 on Monday. Ionis Pharmaceuticals has a 1-year low of $48.27 and a 1-year high of $86.58. The company has a 50-day moving average of $59.09 and a 200 day moving average of $62.89. The firm has a market capitalization of $8.85 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 2.32 and a beta of 1.91. The company has a debt-to-equity ratio of 0.44, a current ratio of 10.39 and a quick ratio of 10.31.
Large investors have recently bought and sold shares of the company. CWM LLC raised its holdings in shares of Ionis Pharmaceuticals by 361.4% in the 2nd quarter. CWM LLC now owns 406 shares of the company’s stock valued at $26,000 after purchasing an additional 318 shares in the last quarter. Quest Capital Management Inc. ADV bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $36,000. Rehmann Capital Advisory Group raised its stake in shares of Ionis Pharmaceuticals by 41.3% during the 2nd quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock worth $38,000 after acquiring an additional 173 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $40,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $49,000. Institutional investors and hedge funds own 85.65% of the company’s stock.
In other news, SVP Richard S. Geary sold 5,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $65.06, for a total value of $325,300.00. Following the completion of the sale, the senior vice president now owns 26,583 shares in the company, valued at approximately $1,729,489.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Joseph Klein III sold 2,000 shares of the business’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the sale, the director now owns 13,495 shares of the company’s stock, valued at approximately $809,700. The disclosure for this sale can be found here. In the last 90 days, insiders sold 37,154 shares of company stock valued at $2,333,382. Company insiders own 2.40% of the company’s stock.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Featured Article: FAANG Stocks
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.